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MAIN MESSAGES
• HbA1c can identify undiagnosed diabetes in white Caucasian, acute medical 
hospital admissions 
• The specificity of HbA1c compared with OGTT for diagnosis of diabetes in 
acute medical admissions with possible diabetes symptoms/complications is 
equivalent to patients at risk of diabetes in the community but the sensitivity is lower 
• The sensitivity of HbA1c for diabetes in hospitalised patients  is higher when 
diagnosed on fasting plasma glucose rather than post glucose load on OGTT
• The discrepancy in diagnoses on HbA1c and OGTT may be explained at least 
in part by transient/stress hyperglycaemia resulting from acute illnesses
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ABSTRACT
OBJECTIVE― To study hyperglycaemia in acute medical admissions to Irish 
regional hospital.
RESEARCH DESIGN AND METHODS― From 2005-2007, 2061 White 
Caucasians, >18 years, were admitted by 1/7 physicians. Those with diabetes 
symptoms/complications but no previous record of hyperglycaemia (n=390), 
underwent OGTT with concurrent HbA1c in  representative subgroup (n=148). 
Comparable data was obtained for 108 primary care patients at risk of diabetes.
RESULTS― Diabetes was diagnosed immediately by routine  practice in 1% 
(22/2061) [age 36(26-61) years (median IQ range)/ 55% (12/22) male with pre-
existing diabetes/dysglycaemia present in 19% (390/2061) [69(58-80) years/ 60% 
(235/390) male].
Possible diabetes symptoms/complications were identified in  19% [70(59-79) 
years/ 57% (223/390) male] with their HbA1c similar to primary care patients 
[54(46-61) years],5.7(5.3-6.0)%/39(34-42) mmol/mol (n=148) v 5.7(5.4-6.1) 
%/39(36-43) mmol/mol, p =0.35, but lower than  those diagnosed on admission, 
10.2(7.4-13.3)%/88(57-122) mmol/mol, p<0.001.
Their fasting plasma glucose (FPG) was similar to primary care patients, 5.2(4.8-
5.7) v 5.2(4.8-5.9) mmol/L, p=0.65, but 2hPG higher, 9.0(7.3-11.4) v 5.5(4.4-7.5), 
p<0.001.
HbA1c identified diabetes in 10% (15/148) with 14 confirmed on OGTT but 
overall 32% (48/148) in diabetic range on OGTT.  
The specificity of HbA1c in 2061 admissions was similar to primary care, 99% v 
96% , p=0.20, but sensitivity  lower, 38% v 93%, p <0.001 (63% on FPG/23% on 
2hPG, p=0.037, in those with possible symptoms/complications).
CONCLUSION― HbA1c can play a diagnostic role in acute medicine as it 
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diagnosed another 2% of admissions with diabetes but the discrepancy in 
sensitivity shows that it does not reflect transient/acute hyperglycaemia from the 
acute medical event.
Keywords
HbA1c
Diagnosis of diabetes
Acute medicine
Oral glucose tolerance test
Stress hyperglycaemia
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INTRODUCTION
Diabetes mellitus is a serious disease causing premature illness and death [1]. It can 
be asymptomatic for many years allowing serious diabetes related complications to
develop [2]. Hospitalised patients are up to three times more likely to have diabetes
(diagnosed or undiagnosed) than those in the community [3, 4] with acute hospital 
admissions rising in affluent countries in line with the aging population [5-7].
Hyperglycaemia can be related to the particular acute medical event for which the 
patient is hospitalised [8]. In evolutionary terms, it is protective improving survival by 
allowing increased entry of glucose into crucial cells [9]. During hospitalisation, it is 
still debatable as to whether tight blood sugar control improves patient outcomes and 
is financially beneficial [10]. As hypoglycaemic episodes may be more problematical 
[11,12], different plasma glucose targets are recommended for patients with diabetes 
in these circumstances [13].
Glucose measurement is essential on admission to hospital as this high risk group may 
not have been screened systematically in the community. Hyperglycaemia, a common 
response to stress associated with acute illness [9], leads to poorer outcomes for 
patients by increasing morbidity and mortality [14-16] and lengthening 
hospitalization. It has been recognised as a major independent predictor of both in-
hospital congestive heart failure and mortality [15, 17].
Current hospital practice involves blood glucose measurement using near patient or 
laboratory testing on admission with follow-up for certain patients in hospital and 
further testing after discharge. The American Diabetes Association (ADA) Clinical 
Practice Recommendations for 2015 suggest using HbA1c to identify hospitalised 
patients with undiagnosed diabetes [10]. Other existing guidelines for acute coronary 
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syndrome include using HbA1c for diagnosis of diabetes although how widely they 
have been adopted is uncertain [8, 18].
As the uptake of HbA1c as a diagnostic test in asymptomatic patients in the 
community has been considerable in the UK, [19, 20], it is now important to assess its 
usefulness in acute medical admissions. In this study, OGTT were performed in 390 
unselected, acute medical admissions identified with symptoms or possible 
complications of diabetes but no prior diagnosis of glucose dysregulation. They were 
admitted to one of the five busiest emergency hospitals in the Republic of Ireland
providing high level services e.g. renal dialysis and cardiac catheterization to around 
480,000 people.  
HbA1c measurement in i) a representative subgroup of admissions with possible 
diabetes symptoms/complications undergoing OGTT (148/390), ii) 20/22 newly 
diagnosed cases of diabetes treated immediately on admission, and, iii) 108 patients at 
risk of diabetes referred for OGTT in primary practice, provides a unique opportunity 
to compare tests for hyperglycaemia in a hospital setting and in the community. 
SUBJECTS
Ethical committee approval was obtained from the Ethics Committees of Waterford 
Regional Hospital and Waterford Institute of Technology and complies with the 
current revision of the Declaration of Helsinki.
This prospective, cross-sectional study was conducted between 1st June 2005 and
31st December 2007 and comprises consecutive, unselected, emergency, medical 
admissions to Waterford Regional Hospital, Ireland, (n=14,432), Fig 1a. All acute 
medical admissions (including cardiovascular disease) presenting to one of seven 
rostered consultant physicians were studied, (n=2,061/14%). A small number of 
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patients were newly diagnosed with diabetes on admission (n=22/1%) and treated 
immediately. Demographic data i.e. age, sex, ethnicity, reason for admission and
diagnosis-related group were obtained from hospital databases, Table 1.
Patients at high risk of diabetes at a primary care practice in Glanmire, Co Cork, 
straddling both suburban and rural areas, were referred in 2007 and 2008 for OGTT
performed according to routine guidance with simultaneous HbA1c measurement in 
108 patients. Fig.1b.
MATERIALS AND METHODS
Inpatients requiring 75g OGTT (n=390/19%) were identified by the consultant 
physician on the post-call ward round within 24 hours of admission. The criteria 
defined in the study for eligibility for OGTT because of possible symptoms or 
complications of diabetes were a) clinical evidence or history of diabetes 
complications i.e. macrovascular disease - coronary heart, cerebrovascular or
peripheral vascular disease or microvascular disease - nephropathy, retinopathy and 
neuropathy or b) risk factors for altered glucose states i.e. obesity, hypertension or
dyslipidaemia, but no prior diagnosis of hyperglycaemia.
No patients refused blood sampling during the study with an OGTT performed by the 
inpatient phlebotomy service on the ward either immediately if fasting or after a 12 
hour, overnight fast supervised by ward nursing staff.  
Laboratory measurements
Venous blood was collected for glucose determination into serum tubes (Greiner Bio-
One Vacuette 2.5ml K3EDTA) either on admission to hospital or during the OGTT. 
Glucose was measured in a routine laboratory on a Beckman LX 20 chemistry 
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analyser (Beckman Coulter Inc) using a glucose oxidase method. Results were 
obtained within 2 to 4 hours of receipt of blood samples following routine procedures 
for emergency/critical care.  HbA1c was measured within a week of admission or 
OGTT by ion exchange, high performance liquid chromatography (IE HPLC) in 
EDTA blood using IFCC- calibrated Menarini 8160 Variant Mode analyser (CV 2.0% 
at 40 mmol/mol and 1.3% at 92 mmol/mol with IFCC reference interval 20-42
mmol/mol/DCCT 4-6%). Blood samples from patients in the community were sent to 
the laboratory at University Hospital Cork for routine measurement of glucose on 
Olympus analysers and HbA1c using IFCC-calibrated Tosoh G7/G8 IE HPLC 
analysers, IFCC reference interval 20-42 mmol/mol/DCCT 4-6%. No patients with 
abnormal haemoglobin were included in the study.
Statistical analysis
Data were entered onto Microsoft Excel, double checked and analysed using SPSS 
version 15.0 for Windows (SPSS Inc, Chicago, Ill, USA) and PASW Statistics 18 
(SPSS Inc., Chicago, Illinois, US). The Mann–Whitney U test was used to generate p 
values in Tables 1 and 2. Both subgroups of patients undergoing OGTT with 
accompanying HbA1c measurement were tested and found to be representative of the 
group as a whole. 
Random or casual plasma glucose was defined as in the diabetic range if ≥11.1 
mmol/L. For fasting plasma glucose, diabetes was defined as plasma glucose ≥7.0 
mmol/L and impaired fasting glucose (IFG) as 6.1-6.9 mmol/L. Two hour plasma 
glucose ≥11.1 mmol/L was defined as diabetes with impaired glucose tolerance 7.8-
11.0 mmol/L [21]. Diabetes was defined as HbA1c ≥ 48 mmol/mol/6.5% according to 
WHO 2011 criteria [22] and prediabetes as HbA1c 42-47 mmol/mol/6.0-6.4%, [23]. 
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For the combined group of acute medical admissions comprising those newly 
diagnosed with diabetes on admission and those with diabetic symptoms and 
complications, the sensitivity of HbA1c was estimated by a weighted average of the 
sensitivities of the two component groups. The weights used were the numbers of 
diagnoses of diabetes that would be expected for each component group within the 
study group of 2061 admissions if the calculated sensitivities were representative. 
Based on a similar assumption, the specificity of the group with diabetic symptoms 
and complications was used as an estimate of the specificity of the combined group. 
Receiver operating characteristic (ROC) curves were produced for i) the combined 
group, ii) the subgroup of acute medical admissions with possible symptoms or 
complications of diabetes and iii) the primary care patients at high risk of diabetes.
Fisher’s Exact test was applied for comparisons of sensitivity and specificity.
RESULTS 
Dysglycaemia in acute medical admissions
During the 30 month study period between 2005 and 2007, 2061 (14%) out of 14432 
inpatients, all white Caucasian, were treated by one of seven admitting consultant 
physicians, Fig. 1a. The burden of dysglycaemia was considerable with 22 (1%) 
diagnosed with diabetes according to routine hospital practice immediately on 
admission (aged 36(26-61) years, median (IQ range), 55% male (12/22); 9 Type 1 
diabetes and 13 Type 2 diabetes). Diagnoses of diabetes, IGT or IFG were established
prior to admission in 390 patients (19%), aged 69(58-80) years, 60% (235/390) male. 
A further 390 (19%), aged 70(59-79) years, 57% (223/390) male, had possible 
symptoms or complications of diabetes on admission and underwent OGTT according 
to study protocol. No routine diagnoses, symptoms or evidence of complications of 
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diabetes were present in 1233 (60%) of the acute medical admissions. Patients were 
excluded from the study, 26 (1%), if aged <18 years, pregnant or diagnosed with 
endocrine disorders i.e. Cushing’s disease, acromegaly, phaeochromocytoma or 
hyperthyroidism. 
Admissions with possible diabetes symptoms or complications
The subgroup of 148/390 (38%) admissions undergoing OGTT with HbA1c measured 
for clinical reasons, Fig.1a, Table 1, were representative of the group as a whole with 
no significant differences between the variables. Similarly so, for the subgroup of 
108/250 (43%) white Caucasian patients at risk of diabetes undergoing OGTT in
primary care, Fig. 1b, who were younger than corresponding inpatients at 54(46-61) v
70(59-79) years, p<0.001, Table 1.
Glycaemic markers in those newly diagnosed with diabetes
Plasma glucose was 19.3 (11.8-27.4) mmol/L in patients diagnosed with diabetes 
immediately on admission and 6.4 (5.6-7.4) mmol/L in patients identified with 
possible symptoms or evidence of diabetic complications. Likewise, HbA1c was 88 
(57-122) mmol/mol or 10.2 (7.4-13.3)%,  and 39 (34-42) mmol/mol or 5.7 (5.3-6.0)%, 
p<0.001, Table 1. HbA1c identified diabetes in 18/20 (90%) of those inpatients 
diagnosed with diabetes immediately on admission. 
HbA1c in at risk patients in hospital and from the community 
HbA1c in inpatients with diabetes symptoms/complications was similar to GP patients 
at risk of diabetes who had not undergone an acute medical event, 39(36-43) 
mmol/mol or 5.7(5.4-6.1)%, p=0.35, Table 1. In the inpatient group, 15/148 (10%) 
had HbA1c ≥48 mmol/mol or 6.5% and, similarly, 17/108 (16%) GP patients, p=0.19, 
Page 12 of 29
Ac
ce
pte
d M
an
us
cri
pt
Page 12 of 12
Table 2.
On OGTT, 32% (48/148) of inpatients with possible symptoms or complications were 
diagnosed with diabetes by OGTT compared with 10% (15/148) on HbA1c, Table 2, a 
reflection of  acute hyperglycaemia induced by the medical emergency. In total, 70% 
(103/148) of inpatients had abnormal glucose status in response to a glucose load as
37% (55) had IGT.  No inpatient displayed IFG only. In comparison, in the GP 
population, 73% (79) were normoglycaemic, 5% (5) had IFG, 10% (10) IGT and 13%
(14) were diagnosed with diabetes, p<0.001.
Distribution of HbA1c and glucose
Probability density functions demonstrate clearly the differences in HbA1c between 
those diagnosed with diabetes immediately on admission, and symptomatic inpatients 
or at risk patients in the community, Fig. 2. The HbA1c probability density functions 
for symptomatic inpatients and at risk patients in the community are very similar, with 
sharp bell shaped curves with maximum heights of 0.77 and 0.74 at 40 mmol/mol and 
are skewed to the right with slight traces up to approximately 100 mmol/mol. The 
corresponding curves for fasting plasma glucose are super-imposable. The HbA1c
curve for inpatients diagnosed immediately on admission is displaced to the right with 
the flattened bell curve (maximum 0.09) extending from  40 mmol/mol to 180 
mmol/mol HbA1c. HbA1c >120 mmol/mol was present in 5 out of 20 patients newly 
diagnosed with diabetes on admission (with HbA1c measured routinely) but not 
detected in admissions with possible symptoms/complications or primary care 
patients.
The probability density functions for 2h plasma glucose demonstrate the nature of 
hyperglycaemia resulting from acute medical incidents with a shift to the right for 
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inpatients with a peak at 8.5 mmol/L compared 5 mmol/L for GP patients, Fig. 2.
Sensitivity and specificity of HbA1c for diabetes
The ability of HbA1c to diagnose diabetes in GP patients was comparable to OGTT 
with the sensitivity being 93% (13/14) and specificity 96% (90/94), Fig. 3. In the 
acute medical admissions studied, the specificity of HbA1c for diagnosis in those 
diagnosed immediately and those with possible symptoms or complications of 
diabetes was 99%, p=0.20, but the sensitivity was significantly lower at 38%, 
p<0.001. In those with possible symptoms or complications only, the sensitivity was 
29% and specificity 99%. The sensitivity was higher for those diagnosed on fasting 
plasma glucose than for those diagnosed on 2h plasma glucose only at 63% (5/8) 
versus 23% (9/40), p=0.037.
DISCUSSION
Hospitals face an ongoing challenge on how to differentiate hyperglycaemia in 
inpatients. The ADA has moved the focus of diagnostic HbA1c testing from 
asymptomatic patients in the community, to the large number of patients who remain 
undiagnosed in settings such as emergency or other hospital wards [10]. In addition to 
previously diagnosed or undiagnosed diabetes, hyperglycaemia in acutely ill patients 
may be induced by insulin resistance resulting from the stress of an acute medical 
event, or result from diabetes induced by glucotoxic drugs such as corticosteroids or 
antipsychotics.
In the white Caucasian patients at high risk of diabetes studied, the distribution of 
fasting plasma glucose on OGTT and HbA1c was similar in acute admissions and
primary care patients, Fig 2. The specificity of HbA1c for diabetes was high in both 
populations justifying its use for diagnostic testing in hospital admissions, Fig.3. 
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However, the sensitivity was lower in inpatients because of the increased prevalence 
of raised 2h plasma glucose on OGTT following the acute medical incident but when 
was examined in terms of fasting and 2h plasma glucose, HbA1c reflected fasting 
plasma glucose better.
In most hospitals random plasma glucose is measured immediately on admission but 
the protocol for HbA1c testing is uncertain. The ADA suggests adding HbA1c
measurement for patients with previously diagnosed diabetes not tested in the 
previous 2 to 3 months and also for those patients at risk of undiagnosed diabetes but 
this guidance is at the level of expert opinion only. The range of HbA1c found in this 
study on admission to hospital or referral from primary care indicate that some 
patients may have had raised blood glucose levels for some time. No cases of 
undiagnosed diabetes presented with HbA1c >120 mmol/mol from those with possible 
diabetic symptoms/complications or primary care but 25% of those diagnosed 
immediately on admission had values >120 mmol/mol considered to be the trigger for 
urgent referral in the UK [19]. Audit data from an ethnically diverse UK region 
demonstrated that one in 200 HbA1c results was above 120 mmol/mol and one in five
patients had undiagnosed diabetes [20]. 
Use of HbA1c in these circumstances should improve the outcome for individual 
hospital patients. Its introduction requires assessment of i) the economic and financial 
situation by country, ii) the practical implications for the laboratory and point of care 
service, iii) the relationship of glucose to HbA1c for different ethnic groups, and iv) 
the effects of medical conditions or drugs on the accuracy of HbA1c relative to glucose
[24-26]. The use of HbA1c for diagnostic purposes in the community has been well 
received in the UK because of its practicality with laboratory requests for HbA1c more 
than doubling since its introduction, glucose decreasing accordingly and requests for 
Page 15 of 29
Ac
ce
pte
d M
an
us
cri
pt
Page 15 of 15
OGTT rare [27].
There is not a perfect correlation between glucose and HbA1c around the diagnostic 
cut-off points. Previous studies have shown that HbA1c <37 mmol/mol (or 5.5%) and 
>58 mmol/mol (or 7.5%) correlate with OGTT at a 95% level but not so highly
between 5.5% and 7.5% [28]. However, this data was analysed before the recent 
recalibration downwards of Tosoh and Bio-Rad analysers [29]. The lack of 
correlation around the diagnostic threshold may be attributed to normal variation in
red blood cell turnover [30, 31]. The specificity and sensitivity of HbA1c reported in 
this paper for the white Caucasian patients in primary care may reflect the prevalence 
of undiagnosed diabetes within the Irish population at the time of the study i.e. 2007 
to 2008.
Certain medical conditions/drugs in individual patients can also affect red blood cell 
turnover. HbA1c has been reported to be depressed by 20 mmol/mol in liver patients 
being assessed for transplantation [27] and up to 40mmol/mol in a patient with 
polycythaemia rubra vera [32].  There is not much quantitative evidence on the 
conditions that may compromise the accuracy of HbA1c relative to glucose outlined 
by WHO in 2011 when recommending HbA1c for diagnosis [22].
Only one HbA1c result was available for this study but the American Diabetes 
Association has now suggested a more measured approach to confirmation of 
diagnoses. They suggest repeats only when feasible or within 3 to 6 months if around 
the diagnostic threshold [10] rather than within two weeks. In patients with very high 
HbA1c, HbA1c should be repeated immediately with an accompanying glucose 
measurement. Although the IE HPLC analysers used in both hospital laboratories 
reported IFCC calibrated HbA1c results, it was reported in 2014 that the Tosoh IE 
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HPLC analysers have a positive bias of +2.4(2.2) mmol/mol or 0.22(0.20)%, mean 
difference and SD, compared to the IFCC secondary reference method and Menarini 
IE HPLC analyser a negligible bias of -0.4(1.2) mmol/mol or 0.04(0.11)% [29].  
Being able to discern whether a patient has stress hyperglycaemia is important as it is 
associated with worse outcomes for patients [33-35]. HbA1c testing cannot identify 
recent transient episodes of hyperglycaemia given the half-life of red blood cells of 2 
to 3 months. Only 29% (14/48) of inpatients with possible complications or symptoms
with diabetes identified on OGTT had the diagnosis confirmed by HbA1c as opposed 
to 93% (13/14) of those from the community. 
HbA1c can identify undiagnosed diabetes depending on the level provide assistance on
whether treatment is required immediately or later during the hospital stay, or whether 
referral to primary care for their diabetes management is adequate. In addition to the 
1% of white Caucasian inpatients diagnosed immediately with diabetes by routine 
methods of the time, another 2% (40/2061) would have been diagnosed by measuring 
HbA1c on admission in those with possible symptoms or complications. 
Comprehensive information needs to be documented in discharge letters to enable 
primary care to continu  to provide suitable diabetes care. It should include data on 
glycaemic status – i) HbA1c, glucose and in some cases fructosamine if HbA1c is not 
suitable, ii) advice on the management of glycaemic control in newly diagnosed 
patients and those previously diagnosed, and iii) the requirements for follow up of 
patients with any  possible symptoms/complications. It is important to ensure that no 
unnecessary anti-hyperglycaemic treatment is continued in patients with transient 
hyperglycaemia caused by an acute medical event. 
In conclusion, this study provides evidence on the use of HbA1c testing in hospital to 
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identify patients with undiagnosed diabetes. It highlights the need for local,  national 
and international guidance to ensure appropriate treatment plans for all patients with 
diabetes and to provide the required follow up if stress hyperglycaemia or possible 
symptoms or complications of diabetes are evident on hospitalisation. 
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FIGURE LEGENDS
Figure 1a
Flowchart for acute medical admissions identifying patients diagnosed with diabetes 
immediately and patients undergoing OGTT because of symptoms or complications of 
diabetes. 
Figure 1b
Flowchart outlining patients in the community at risk of diabetes undergoing OGTT at 
GP practice. 
Figure 2
Probability density functions for HbA1c in patients newly diagnosed with diabetes on 
admission to hospital or with possible symptoms/complications of diabetes. Also for 
glucose on OGTT in inpatients with possible symptoms/complications of diabetes and 
high risk patients referred to GP.
Grey GP referrals at risk of diabetes n=108; Turquoise Acute medical admissions with 
possible symptoms or complications of diabetes n=148; Green Acute medical 
admissions diagnosed with diabetes immediately n=20
HbA1c solid lines; FPG  -----; 2hPG on OGTT …...
Figure 3
Receiver operator curves for use of HbA1c for diagnosis of diabetes in i) Grey line 
108 patients at risk of diabetes diagnosed on OGTT by GP, ii) Purple line 22 acute 
medical admissions newly diagnosed routinely with diabetes and 390 with possible 
symptoms or /complications (data extrapolated from OGTT subgroup) and iii) 
Turquoise line subgroup of acute medical admissions with possible symptoms or 
complications of diabetes undergoing OGTT (n=148). Arrows indicate cutpoint for 
diagnosis of diabetes ≥48 mmol/mol or 6.5% followed by sensitivity (%) and 
specificity (%).
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Table 1—HbA1c at OGTT in acute medical admissions with possible symptoms or 
complications of diabetes and patients at high risk of diabetes from general practice
Acute medical 
admissions with
possible symptoms/ 
complications of DM
GP patients  at 
high risk of 
diabetes
p value
N 148 108 -
Age (years)* 70 (59–79) 54 (46–61) <0.001
White Caucasian (%) 148 (100%) 108 (100%) 1.00
Male (%) 93 (63%) NA -
Reason for admission to hospital
CVD 85/57% - -
Stroke or TIA 19/13%
Respiratory 11/7%
Endocrine disorders 6/4%
Other (%) 27/18%
Plasma glucose (mmol/L)
Admission*          6.4 (5.6–7.4) - -
Fasting plasma glucose* 5.2 (4.8–5.7) 5.2 (4.8–5.9) 0.65
2h plasma glucose*        9.0 (7.3–11.4) 5.5 (4.4–7.5) <0.001
HbA1c  (mmol/mol)* 39 (34–42) 39 (36–43)
HbA1c (%)*  5.7 (5.3–6.0) 5.7 (5.4–6.1)
0.35
* Median (IQ range)
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Table 2—Glycaemic status on OGTT and HbA1c ≥6.5% or 48 mmol/mol in acute 
medical admissions and GP referrals in white Caucasian patients from Ireland
Median (IQ range)
Admissions 
n=148
GP referrals 
n=108
Admissions 
n=148
GP referrals 
n=108
Status
HbA1c
% 
mmol/mol
HbA1c
%
mmol/mol
p value
for 
HbA1c Prevalence Prevalence 
p value
for 
prevalence
On HbA1c 
Normal 5.7 (5.3–10.7) 5.5 (5.3–5.7) 0.75 104 (70%) 72 (67%) 0.59
39 (34–93) 37 (34–39)
Pre-diabetes 6.1 (6.0–6.3) 6.1 (6.0–6.3) 0.96 29 (20%) 19 (18%) 0.75
43 (42–45) 43 (42–45)
DM 7.0 (6.7–8.0) 8.0 (7.1–9.5) 0.08 15 (10%) 17 (16%) 0.19
53 (50–64) 64 (54–80)
DM both 7.1 (6.7–8.2) 8.3 (7.3–9.6) 0.056 14 (9%) 13 (12%) 0.54
54 (50–66) 67 (56–81)
DM HbA1c only 6.5 / 48 7.1 (6.6–8.7) 0.60 1 (1%) 4 (4%) 0.17
54 (49–72)
DM OGTT only 5.8 (5.4–6.0) 5.7 1.00 34 (23%) 1 (1%) <0.001
40 (36–42) 39
On OGTT 
NG 5.6 (5.2–5.8) 5.6 (5.3–5.9) 0.21 45 (30%) 79 (73%) <0.001
38 (33–40) 38 (34–41)
IFG only - 6.0 (5.5–6.6) - 0 (0%) 5 (5%) 0.013
42 (37–49)
IGT only 5.7 (5.4–6.0) 5.9 (5.5–7.0) 0.31 47 (32%) 6 (6%) <0.001
39 (36–42) 41 (37–53)
IFG & IGT 5.7 (5.0–6.3) 6.2 (5.9–6.8) 0.14 8 (5%) 4 (4%) 0.77
39 (31–45) 44 (41–51)
DM 6.0 (5.6–6.7) 8.2 (7.1–9.6) <0.001 48 (32%) 14 (13%) <0.001
42 (38–50) 66 (54–81)
DM on FPG 6.9 (5.8–10.2) 8.2 (7.1–9.6) 0.37 8 (5%) 14 (13%) 0.042
52 (40–88) 66 (54–81)
DM on 2hPG 6.0 (5.6–6.7) 8.5 (7.6–9.6) <0.001 47 (32%) 12 (11%) <0.001
42 (38–50) 69 (60–81)
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